Is prostate cancer different in black men? Answers from 3 natural history models

Alex Tsodikov, Roman Gulati, Tiago M. de Carvalho, Eveline A.M. Heijnsdijk, Rachel A. Hunter-Merrill, Angela B. Mariotto, Harry J. de Koning, Ruth Etzioni

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

BACKGROUND: Black men in the United States have substantially higher prostate cancer incidence rates than the general population. The extent to which this incidence disparity is because prostate cancer is more prevalent, more aggressive, and/or more frequently diagnosed in black men is unknown. METHODS: The authors estimated 3 independently developed models of prostate cancer natural history in black men and in the general population using an updated reconstruction of prostate-specific antigen screening, based on the National Health Interview Survey in 2005 and on prostate cancer incidence data from the Surveillance, Epidemiology, and End Results program during 1975 through 2000. By using the estimated models, the natural history of prostate cancer was compared between black men and the general population. RESULTS: The models projected that from 30% to 43% (range across models) of black men develop preclinical prostate cancer by age 85 years, a risk that is (relatively) 28% to 56% higher than that in the general population. Among men who had preclinical disease onset, black men had a similar risk of diagnosis (range, 35%-49%) compared with the general population (32%-44%), but their risk of progression to metastatic disease by the time of diagnosis was from 44% to 75% higher than that in the general population. CONCLUSIONS: Prostate cancer incidence patterns implicate higher incidence of preclinical disease and higher risk of metastatic progression among black men. The findings suggest screening black men earlier than white men and support further research into the benefit-harm tradeoffs of more aggressive screening policies for black men. Cancer 2017;123:2312–2319.

Original languageEnglish (US)
Pages (from-to)2312-2319
Number of pages8
JournalCancer
Volume123
Issue number12
DOIs
StatePublished - Jun 15 2017
Externally publishedYes

Fingerprint

Natural History
Prostatic Neoplasms
Incidence
Population
SEER Program
Prostate-Specific Antigen
Health Surveys
Interviews

Keywords

  • cancer epidemiology
  • mass screening
  • natural history
  • prostate-specific antigen
  • prostatic neoplasms
  • racial disparities
  • statistical methods and models

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tsodikov, A., Gulati, R., de Carvalho, T. M., Heijnsdijk, E. A. M., Hunter-Merrill, R. A., Mariotto, A. B., ... Etzioni, R. (2017). Is prostate cancer different in black men? Answers from 3 natural history models. Cancer, 123(12), 2312-2319. https://doi.org/10.1002/cncr.30687

Is prostate cancer different in black men? Answers from 3 natural history models. / Tsodikov, Alex; Gulati, Roman; de Carvalho, Tiago M.; Heijnsdijk, Eveline A.M.; Hunter-Merrill, Rachel A.; Mariotto, Angela B.; de Koning, Harry J.; Etzioni, Ruth.

In: Cancer, Vol. 123, No. 12, 15.06.2017, p. 2312-2319.

Research output: Contribution to journalArticle

Tsodikov, A, Gulati, R, de Carvalho, TM, Heijnsdijk, EAM, Hunter-Merrill, RA, Mariotto, AB, de Koning, HJ & Etzioni, R 2017, 'Is prostate cancer different in black men? Answers from 3 natural history models', Cancer, vol. 123, no. 12, pp. 2312-2319. https://doi.org/10.1002/cncr.30687
Tsodikov A, Gulati R, de Carvalho TM, Heijnsdijk EAM, Hunter-Merrill RA, Mariotto AB et al. Is prostate cancer different in black men? Answers from 3 natural history models. Cancer. 2017 Jun 15;123(12):2312-2319. https://doi.org/10.1002/cncr.30687
Tsodikov, Alex ; Gulati, Roman ; de Carvalho, Tiago M. ; Heijnsdijk, Eveline A.M. ; Hunter-Merrill, Rachel A. ; Mariotto, Angela B. ; de Koning, Harry J. ; Etzioni, Ruth. / Is prostate cancer different in black men? Answers from 3 natural history models. In: Cancer. 2017 ; Vol. 123, No. 12. pp. 2312-2319.
@article{e5813ac8dd2f46818322b503de2dd25c,
title = "Is prostate cancer different in black men? Answers from 3 natural history models",
abstract = "BACKGROUND: Black men in the United States have substantially higher prostate cancer incidence rates than the general population. The extent to which this incidence disparity is because prostate cancer is more prevalent, more aggressive, and/or more frequently diagnosed in black men is unknown. METHODS: The authors estimated 3 independently developed models of prostate cancer natural history in black men and in the general population using an updated reconstruction of prostate-specific antigen screening, based on the National Health Interview Survey in 2005 and on prostate cancer incidence data from the Surveillance, Epidemiology, and End Results program during 1975 through 2000. By using the estimated models, the natural history of prostate cancer was compared between black men and the general population. RESULTS: The models projected that from 30{\%} to 43{\%} (range across models) of black men develop preclinical prostate cancer by age 85 years, a risk that is (relatively) 28{\%} to 56{\%} higher than that in the general population. Among men who had preclinical disease onset, black men had a similar risk of diagnosis (range, 35{\%}-49{\%}) compared with the general population (32{\%}-44{\%}), but their risk of progression to metastatic disease by the time of diagnosis was from 44{\%} to 75{\%} higher than that in the general population. CONCLUSIONS: Prostate cancer incidence patterns implicate higher incidence of preclinical disease and higher risk of metastatic progression among black men. The findings suggest screening black men earlier than white men and support further research into the benefit-harm tradeoffs of more aggressive screening policies for black men. Cancer 2017;123:2312–2319.",
keywords = "cancer epidemiology, mass screening, natural history, prostate-specific antigen, prostatic neoplasms, racial disparities, statistical methods and models",
author = "Alex Tsodikov and Roman Gulati and {de Carvalho}, {Tiago M.} and Heijnsdijk, {Eveline A.M.} and Hunter-Merrill, {Rachel A.} and Mariotto, {Angela B.} and {de Koning}, {Harry J.} and Ruth Etzioni",
year = "2017",
month = "6",
day = "15",
doi = "10.1002/cncr.30687",
language = "English (US)",
volume = "123",
pages = "2312--2319",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Is prostate cancer different in black men? Answers from 3 natural history models

AU - Tsodikov, Alex

AU - Gulati, Roman

AU - de Carvalho, Tiago M.

AU - Heijnsdijk, Eveline A.M.

AU - Hunter-Merrill, Rachel A.

AU - Mariotto, Angela B.

AU - de Koning, Harry J.

AU - Etzioni, Ruth

PY - 2017/6/15

Y1 - 2017/6/15

N2 - BACKGROUND: Black men in the United States have substantially higher prostate cancer incidence rates than the general population. The extent to which this incidence disparity is because prostate cancer is more prevalent, more aggressive, and/or more frequently diagnosed in black men is unknown. METHODS: The authors estimated 3 independently developed models of prostate cancer natural history in black men and in the general population using an updated reconstruction of prostate-specific antigen screening, based on the National Health Interview Survey in 2005 and on prostate cancer incidence data from the Surveillance, Epidemiology, and End Results program during 1975 through 2000. By using the estimated models, the natural history of prostate cancer was compared between black men and the general population. RESULTS: The models projected that from 30% to 43% (range across models) of black men develop preclinical prostate cancer by age 85 years, a risk that is (relatively) 28% to 56% higher than that in the general population. Among men who had preclinical disease onset, black men had a similar risk of diagnosis (range, 35%-49%) compared with the general population (32%-44%), but their risk of progression to metastatic disease by the time of diagnosis was from 44% to 75% higher than that in the general population. CONCLUSIONS: Prostate cancer incidence patterns implicate higher incidence of preclinical disease and higher risk of metastatic progression among black men. The findings suggest screening black men earlier than white men and support further research into the benefit-harm tradeoffs of more aggressive screening policies for black men. Cancer 2017;123:2312–2319.

AB - BACKGROUND: Black men in the United States have substantially higher prostate cancer incidence rates than the general population. The extent to which this incidence disparity is because prostate cancer is more prevalent, more aggressive, and/or more frequently diagnosed in black men is unknown. METHODS: The authors estimated 3 independently developed models of prostate cancer natural history in black men and in the general population using an updated reconstruction of prostate-specific antigen screening, based on the National Health Interview Survey in 2005 and on prostate cancer incidence data from the Surveillance, Epidemiology, and End Results program during 1975 through 2000. By using the estimated models, the natural history of prostate cancer was compared between black men and the general population. RESULTS: The models projected that from 30% to 43% (range across models) of black men develop preclinical prostate cancer by age 85 years, a risk that is (relatively) 28% to 56% higher than that in the general population. Among men who had preclinical disease onset, black men had a similar risk of diagnosis (range, 35%-49%) compared with the general population (32%-44%), but their risk of progression to metastatic disease by the time of diagnosis was from 44% to 75% higher than that in the general population. CONCLUSIONS: Prostate cancer incidence patterns implicate higher incidence of preclinical disease and higher risk of metastatic progression among black men. The findings suggest screening black men earlier than white men and support further research into the benefit-harm tradeoffs of more aggressive screening policies for black men. Cancer 2017;123:2312–2319.

KW - cancer epidemiology

KW - mass screening

KW - natural history

KW - prostate-specific antigen

KW - prostatic neoplasms

KW - racial disparities

KW - statistical methods and models

UR - http://www.scopus.com/inward/record.url?scp=85018861259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018861259&partnerID=8YFLogxK

U2 - 10.1002/cncr.30687

DO - 10.1002/cncr.30687

M3 - Article

VL - 123

SP - 2312

EP - 2319

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -